 "Lupin launches generic Tamiflu treatment capsules in US market")
Drug firm Lupin today said it has launched in the US market its generic Oseltamivir Phosphate capsules, used for treatment of influenza.
The company said in a BSE filing that it has launched its tablets after receiving the approval from the United States Food and Drug Administration (USFDA).
The capsules, in the strengths of 30 mg, 45 mg and 75 mg, are generic versions of Hoffman-La Roche Inc's Tamiflu capsules in the same strengths, it added.
The product is "indicated for the treatment of acute, uncomplicated influenza A and B in patients two weeks of age and older who have been symptomatic for no more than 48 hours, and prophylaxis of influenza A and B in patients one year and older", Lupin said.
The capsules had annual sales of about USD 518 million in the US as per IQVIA MAT December 201 data, it added.
Lupin Ltd stock was trading 2.81 per cent higher at Rs 843.95 in the afternoon trade on BSE.
The company said in a BSE filing that it has launched its tablets after receiving the approval from the United States Food and Drug Administration (USFDA).
The capsules, in the strengths of 30 mg, 45 mg and 75 mg, are generic versions of Hoffman-La Roche Inc's Tamiflu capsules in the same strengths, it added.
Also Read
The capsules had annual sales of about USD 518 million in the US as per IQVIA MAT December 201 data, it added.
Lupin Ltd stock was trading 2.81 per cent higher at Rs 843.95 in the afternoon trade on BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%